Its ligand, CXCL16, can be expressed by cancer cells and antigen-presenting cells (APCs), and the interaction of the two has been found to play a key role in recruiting and retaining TRMs in various tissue contexts (Figure 2) [12,13]. The gene discussed is CXCL16; the disease is cancer.